Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764607 · ClinicalTrials.gov registry record · Phase 2
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01764607 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 1 participants.
The verdict
NCT01764607, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer. The use of immunosuppressant or anti-rejection drugs that are needed after SOTR is known to increase the risk of developing certain kinds of cancer. The purpose of this study is to find out how well Sirolimus (also known as Rapamune) works at treating squamous cell carcinoma in renal transplant patients.
Interventions
- DRUG Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764607
The ClinicalTrials.gov registry entry for NCT01764607 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.
NCT01764607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01764607 about?
NCT01764607 is a clinical study titled "Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma". Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer. The use of immunosuppressant or anti-rejection drugs that are needed after SOTR is known to increase the risk of developing certain kind...
What is the current status of trial NCT01764607?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2013-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01764607?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT01764607?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.